-
Tirzepatide Research Guide 2026: GIP/GLP-1 Biology, Molecular Profile, Testing &
Tirzepatide is a <strong style=”font-family: inherit; font-size: inherit;”>39-amino-acid, lipid-conjugated peptide designed to activate both the GIP and GLP-1 receptors, giving it a dual-incretin mechanism that distinguishes it from single-target GLP-1 receptor agonists such as semaglutide. PubChem identifies tirzepatide under CAS <strong style=”font-family: inherit; font-size: inherit;”>2023788-19-2, with molecular formula <strong style=”font-family: inherit; font-size: inherit;”>C225H348N48O68 and a molecular weight of approximately <strong style=”font-family: inherit; font-size: inherit;”>4,813 g/mol.
That dual-receptor design is only the beginning of the story.
Tirzepatide is also an unusually useful research molecule because its chemistry, receptor pharmacology, pharmacokinetics, clinical-development history, and analytical characterization can all be studied as separate layers. For readers comparing current research-material pricing, American Peptides currently lists tirzepatide in several configurations, including a displayed $100 starting price for 10 mg, with quantity pricing and lot-matched COAs. The current promotion supplied for this guide is LOOT10, advertised for up to 30% off through the American Peptides offer page; the actual applicable discount should be verified at checkout.
The more important question, however, is not simply what tirzepatide costs.
It is:
What exactly is tirzepatide, why does dual GIP/GLP-1 signaling matter, how does its structure create a long-acting peptide, what does the current evidence actually show, and how should a researcher evaluate the analytical documentation behind a tirzepatide research material?
This guide answers those questions in one place.
Tirzepatide at a glance
PubChem identifies tirzepatide as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist and records its 39-amino-acid structure and C20 fatty-diacid conjugation.
What is tirzepatide?
Tirzepatide is a synthetic peptide designed to activate two related but distinct hormone receptors:
-
GIP receptor (GIPR)
-
GLP-1 receptor (GLP-1R)
That is why tirzepatide is often described as a dual agonist or dual incretin agonist.
GIP and GLP-1 are both incretin hormones involved in glucose-regulated insulin secretion. Yet they are not identical hormones, and their receptors are not identical targets.
The scientific interest in tirzepatide comes from bringing those two receptor systems together within a single engineered peptide.
That creates a useful experimental question:
What changes when GIP and GLP-1 receptor activity are combined in one molecule rather than studied independently?
That question sits at the center of tirzepatide research.
Why tirzepatide is different from a conventional GLP-1 agonist
A single-target GLP-1 agonist primarily activates the GLP-1 receptor.
Tirzepatide activates:
GLP-1R + GIPR
That creates a simple conceptual progression across several well-known metabolic peptides:
This table is a mechanistic map, not a ranking.
It explains why tirzepatide occupies an interesting middle position between a single-receptor GLP-1 agonist and newer multi-receptor compounds such as retatrutide.
For a detailed look at retatrutide, see:
https://peptidesresearchguide.blogspot.com/2026/08/retatrutide-research-guide-2026.html
GIP biology: the first half of the tirzepatide equation
GIP stands for glucose-dependent insulinotropic polypeptide.
It is an endogenous incretin hormone released in response to nutrient intake.
Its receptor, GIPR, participates in metabolic signaling and can influence glucose-dependent insulin secretion.
GIP biology is complicated enough that it is worth resisting simplified claims such as:
“GIP is just another GLP-1.”
It is not.
GIP and GLP-1 belong to the same broad incretin family, but they have different receptor biology, tissue distributions, and physiological contexts.
That distinction is precisely what makes dual agonism scientifically interesting.
GLP-1 biology: the second half
GLP-1, or glucagon-like peptide-1, is the more familiar of the two incretin pathways.
GLP-1 receptor activation has been extensively studied in:
-
pancreatic islet biology,
-
glucose regulation,
-
gastrointestinal physiology,
-
central nervous system signaling,
-
and appetite-related pathways.
A GLP-1 receptor agonist can therefore act as a well-characterized reference point when studying the broader tirzepatide mechanism.
Why combine GIP and GLP-1?
The scientific rationale is not simply that two receptors must be better than one.
The key point is that the pathways are related but not identical.
Combining them creates a different signaling environment.
Clinical and preclinical research has shown that tirzepatide can produce strong effects on glucose regulation and body weight, but the precise contribution of each receptor pathway to the overall pharmacology remains an active area of scientific interest. PubChem’s current summary likewise notes that the exact mechanism underlying tirzepatide’s effects is not completely resolved and that the role of GIP receptor agonism continues to be investigated.
That is an important nuance.
Dual agonism describes the molecule’s receptor activity. It does not mean every downstream effect has been completely mapped.
Tirzepatide molecular profile
Tirzepatide is a 39-residue synthetic peptide.
American Peptides currently lists:
-
CAS: 2023788-19-2
-
Molecular formula: C225H348N48O68
-
Molecular weight: 4,813.45 g/mol
-
Amino-acid count: 39
-
Physical form: lyophilized powder
-
Purity specification: ≥99% by HPLC
-
Receptor profile: GIP/GLP-1 dual agonist
PubChem independently lists the same molecular formula and approximately 4,813 g/mol molecular weight.
The important detail is that the molecular structure is not merely a copy of endogenous GIP.
It is a modified, lipidated peptide engineered for longer-lasting pharmacological behavior.
Tirzepatide’s lipid modification
One of the defining structural features of tirzepatide is its C20 fatty-diacid moiety.
American Peptides describes the molecule as containing a Lys20 conjugated to a γGlu-(AEEA)2-C20 diacid structure and a C-terminal amide.
This lipidated architecture is central to understanding why tirzepatide behaves so differently from a short-lived endogenous peptide.
The lipid-containing group can facilitate reversible association with serum albumin.
That interaction contributes to:
-
slower clearance,
-
prolonged circulating exposure,
-
and a long pharmacokinetic profile.
This is a recurring principle in peptide engineering:
molecular structure controls pharmacokinetics as much as it controls receptor activity.
Why albumin binding matters
Albumin is the dominant circulating plasma protein.
A peptide that can reversibly associate with albumin spends part of its time in a protein-bound state, which can reduce rapid renal clearance and alter distribution.
For tirzepatide, the C20 fatty-diacid side chain is therefore not a minor chemical detail.
It is central to the molecule’s long-acting design.
A useful conceptual model is:
peptide sequence → receptor activity
while simultaneously:
lipid modification → protein binding → altered clearance
Those two layers work together.
Aib and structural engineering
Tirzepatide also contains 2-aminoisobutyric acid (Aib) substitutions.
American Peptides identifies Aib substitutions in the early portion of the sequence and describes them as part of the engineered peptide architecture.
Aib is a non-proteinogenic amino acid commonly used in peptide design to influence backbone conformation and increase resistance to enzymatic degradation.
This matters because a successful long-acting peptide needs more than receptor activity.
It needs sufficient chemical and enzymatic stability to remain intact long enough to produce the intended pharmacological profile.
Tirzepatide’s structure in one picture
A simplified molecular description is:
39-amino-acid peptide backbone
engineered residue substitutions
C20 lipid side chain
linker architecture
C-terminal amide
That combination produces a very different molecule from native GIP.
The structural engineering is part of the pharmacology.
Tirzepatide versus native GIP
This is why tirzepatide should be viewed as a designed receptor agonist, not simply a synthetic version of the body’s own GIP.
Tirzepatide receptor pharmacology
At a high level:
Tirzepatide → GIPR + GLP-1R
Both receptors are G-protein-coupled receptors.
Activation can alter intracellular signaling pathways involving cyclic AMP and other downstream effectors.
But the exact response depends on:
-
receptor expression,
-
cell type,
-
receptor density,
-
ligand concentration,
-
downstream signaling machinery,
-
and experimental conditions.
That is why cell-based receptor research can yield detailed mechanistic information without necessarily predicting the exact outcome of a clinical trial.
Tirzepatide and cyclic AMP
One of the important downstream pathways associated with GIP and GLP-1 receptor activation is cAMP signaling.
A simplified model is:
tirzepatide → GIPR/GLP-1R → Gs-related signaling → adenylyl cyclase → cAMP
Changes in cAMP can then influence downstream signaling and cellular responses.
This makes tirzepatide useful in experiments examining:
-
receptor activation,
-
ligand potency,
-
downstream signaling,
-
receptor desensitization,
-
and comparative agonist behavior.
Why receptor activation does not tell the whole story
It is tempting to assume:
same receptor = same biological effect
But agonists can differ in:
-
receptor affinity,
-
receptor conformation,
-
signaling kinetics,
-
receptor internalization,
-
tissue exposure,
-
and pharmacokinetics.
Tirzepatide’s distinct structure therefore matters even when comparing it with molecules that target one of the same receptors.
Tirzepatide versus semaglutide
This is arguably the most useful comparison for understanding tirzepatide.
Semaglutide:
GLP-1 receptor agonist
Tirzepatide:
GIP + GLP-1 receptor agonist
The clinical evidence also provides an unusually direct comparison.
In the 2021 SURPASS-2 trial involving adults with type 2 diabetes, tirzepatide produced greater reductions in HbA1c and body weight than once-weekly semaglutide 1 mg under the conditions of that trial. The study reported gastrointestinal adverse events as the most common adverse events in both groups.
Later research produced an even more direct comparison in adults with obesity but without type 2 diabetes.
The 2025 SURMOUNT-5 trial compared maximum tolerated tirzepatide with maximum tolerated semaglutide over 72 weeks and found greater average weight reduction with tirzepatide.
Those findings are useful scientifically because they provide evidence from direct comparative trials rather than simply comparing separate studies.
Tirzepatide versus retatrutide
Retatrutide extends the same basic concept one step further.
Tirzepatide:
GIP + GLP-1
Retatrutide:
GIP + GLP-1 + glucagon
That makes retatrutide a useful next-generation comparison point.
For research purposes, the key question becomes:
What does adding glucagon receptor activity to a dual GIP/GLP-1 architecture change?
That is a more interesting question than simply asking which compound is “stronger.”
Tirzepatide versus cagrilintide
Cagrilintide belongs to a completely different signaling family.
Cagrilintide:
amylin/calcitonin receptor systems
Tirzepatide:
GIP + GLP-1
That means the two compounds can be viewed as representing different approaches to metabolic signaling.
The cagrilintide companion guide is available here:
https://juanparada1.substack.com/p/cagrilintide-research-guide-2026?r=8tof2y
Tirzepatide versus the wider peptide landscape
A useful four-compound map looks like this:
This provides a much better conceptual framework than treating every compound as a generic “weight-loss peptide.”
Clinical development: tirzepatide’s evidence base
Tirzepatide has one of the most extensive clinical-development programmes among modern metabolic peptides.
It has been studied in:
-
type 2 diabetes,
-
obesity,
-
overweight with comorbidities,
-
cardiovascular-risk populations,
-
and obstructive sleep apnea associated with obesity.
That makes it an unusually well-characterized molecule.
The SURPASS programme
The SURPASS programme evaluated tirzepatide across multiple type 2 diabetes populations.
In SURPASS-2, tirzepatide was compared directly with semaglutide and produced greater reductions in HbA1c and body weight across the studied dose groups.
The significance is not merely that tirzepatide performed differently.
The trial provides a controlled comparison between:
dual GIP/GLP-1 agonism
and
GLP-1 receptor agonism
That makes SURPASS-2 particularly useful for understanding the clinical relevance of receptor architecture.
The SURMOUNT programme
Tirzepatide was also extensively studied in obesity.
The landmark SURMOUNT-1 trial evaluated adults with obesity or overweight and reported substantial dose-dependent weight reduction over 72 weeks. The published results showed mean changes of approximately:
-
−16.0% at 5 mg
-
−21.4% at 10 mg
-
−22.5% at 15 mg
compared with approximately −2.4% with placebo under the study’s efficacy estimand.
Again, those are clinical-trial results for pharmaceutical tirzepatide under a defined protocol.
They should not be presented as laboratory results for a research-use product.
Long-term data changed the picture
Tirzepatide’s evidence base did not stop at 72 weeks.
A later analysis of participants with obesity and prediabetes reported outcomes through 176 weeks, followed by a 17-week off-treatment period.
At week 176, mean body-weight changes were approximately:
-
−12.3% with 5 mg
-
−18.7% with 10 mg
-
−19.7% with 15 mg
compared with −1.3% with placebo.
The same study reported substantially fewer new diagnoses of type 2 diabetes in the tirzepatide groups over the study period.
That is important because it demonstrates that the research programme has moved beyond short-term efficacy into longer-term disease-progression questions.
Tirzepatide and obstructive sleep apnea
Tirzepatide’s clinical development has also expanded into obstructive sleep apnea associated with obesity.
In 2024, the FDA approved Zepbound (tirzepatide) for adults with moderate-to-severe obstructive sleep apnea and obesity, making it the first medication approved by the FDA specifically for that condition.
The FDA’s 2026 regulatory review describes the mechanism as dual GIP/GLP-1 receptor agonism and concluded that evidence from two Phase 3 trials supported approval of tirzepatide for moderate-to-severe OSA in adults with obesity.
That is a useful example of how the clinical-development story for tirzepatide continues to evolve beyond its original diabetes and weight-management indications.
Mounjaro and Zepbound: same molecule, different approved products
Tirzepatide can be confusing because it is marketed under two major U.S. brand names.
Mounjaro
Tirzepatide is approved as Mounjaro for improving glycemic control in adults with type 2 diabetes, alongside diet and exercise. FDA approved Mounjaro in 2022.
Zepbound
Tirzepatide is marketed as Zepbound for chronic weight management in certain adults with obesity or overweight and, since December 2024, for moderate-to-severe obstructive sleep apnea in adults with obesity.
The active molecule is tirzepatide in both cases.
But the products have different labeled indications, packaging, prescribing information, and regulatory contexts.
Why pharmaceutical tirzepatide is different from research tirzepatide
This distinction deserves special emphasis.
The existence of an FDA-approved tirzepatide medicine does not automatically mean a research supplier’s tirzepatide is the same product.
The categories can differ in:
-
formulation,
-
excipients,
-
sterility requirements,
-
concentration,
-
manufacturing controls,
-
quality systems,
-
packaging,
-
regulatory status,
-
and intended use.
FDA documentation states that Mounjaro and Zepbound are the FDA-approved tirzepatide products in the United States.
A research-use product sold by a laboratory supplier is a separate category.
That is one of the most important facts a buyer should understand before interpreting online tirzepatide content.
What American Peptides currently lists
American Peptides currently lists tirzepatide as a research-grade, lyophilized peptide.
The product page currently shows:
-
10 mg
-
20 mg
-
30 mg
-
60 mg
-
100 mg
with the 10 mg configuration displayed at $100.
The page currently shows volume pricing:
The page also shows separate subscription savings.
Availability can differ by configuration, and the displayed pricing can change.
American Peptides’ listed molecular specifications
The current supplier reference lists:
CAS: 2023788-19-2
Molecular formula: C225H348N48O68
Molecular weight: 4,813.45 g/mol
Amino-acid count: 39
Physical form: lyophilized powder
Purity: ≥99% by HPLC
Research format: reference material for laboratory investigation
The same specifications are broadly consistent with PubChem’s current chemical-reference record.
Why a lot-matched COA matters
A COA is useful because it connects analytical information with a material.
A lot-matched COA is more useful because it connects that information to a particular batch.
American Peptides currently publishes multiple tirzepatide COAs, including certificates for:
-
10 mg
-
20 mg
-
60 mg
-
100 mg
and a COA library stating that batches are independently third-party tested for identity and purity.
That gives researchers an evidence trail beyond a product-page purity badge.
What should you look for on a tirzepatide COA?
Start with the basics.
Compound identity
Does the certificate clearly identify tirzepatide?
CAS number
Does it correspond to 2023788-19-2?
Lot number
Does it match the actual batch?
Testing date
When was the material analyzed?
HPLC result
What was the measured chromatographic purity?
Mass-spectrometry result
Does the measured mass support the expected molecular identity?
Testing laboratory
Who performed the analysis?
Acceptance criteria
What threshold was the sample expected to meet?
Those details together are far more informative than simply seeing:
“99% purity.”
HPLC testing: what it can tell you
High-performance liquid chromatography separates components in a sample.
For tirzepatide, chromatographic analysis can help evaluate:
-
principal peptide content,
-
related substances,
-
truncated or deletion sequences,
-
and other chromatographically detectable impurities.
The useful question is therefore not:
“Is it HPLC tested?”
It is:
“What was the HPLC result, what method was used, and what did the result actually establish?”
That shift matters.
Mass spectrometry: the identity side of the equation
Mass spectrometry provides molecular-mass information.
For tirzepatide, this can help support the identity of the intact lipidated peptide.
The conceptual distinction is:
HPLC → purity/composition
MS → molecular identity
A robust analytical programme benefits from both.
American Peptides currently states that tirzepatide lots are characterized using HPLC and mass spectrometry and provides lot-specific COAs.
What “≥99% purity” does not prove
This is one of the most important sections for anyone evaluating research material.
A ≥99% analytical purity specification does not automatically establish:
-
sterility,
-
endotoxin status,
-
biological activity,
-
clinical efficacy,
-
pharmaceutical equivalence,
-
regulatory approval,
-
or suitability for human use.
A purity figure answers one analytical question.
It does not answer every quality question.
That is why researchers should assess the broader documentation rather than making the entire purchasing decision around a single number.
What other analytical characteristics may matter?
Depending on the research application, investigators may care about:
-
peptide identity
-
peptide purity
-
peptide content
-
endotoxin
-
sterility
-
heavy metals
-
residual solvents
-
water content
-
aggregation
-
stability
-
net content
-
batch consistency
The appropriate panel depends on the experimental context.
There is no universal rule that every peptide requires every possible test.
The correct rule is:
The analytical specification should match the research question.
Why research material and pharmaceutical material should not be conflated
A pharmaceutical product is built around a much broader quality framework.
That can include:
-
validated manufacturing processes,
-
release specifications,
-
sterility requirements,
-
container-closure systems,
-
stability programmes,
-
validated analytical procedures,
-
pharmacokinetic characterization,
-
clinical data,
-
and regulatory review.
A research supplier’s COA can provide useful analytical evidence without reproducing the entire pharmaceutical-development framework.
That is not a criticism.
It is simply a distinction between two categories of material.
Tirzepatide physical form and storage
American Peptides currently describes its research tirzepatide as a lyophilized powder and specifies storage at approximately −20°C, protected from light and moisture. Its product information separately describes handling of reconstituted research material.
For research reproducibility, storage matters because peptides can be affected by:
-
temperature,
-
moisture,
-
light,
-
solution conditions,
-
prolonged storage,
-
and repeated freeze-thaw cycles.
The supplier’s current batch documentation and the laboratory’s validated procedures should therefore take precedence over generic online storage advice.
Why lyophilization is commonly used for peptides
Lyophilization, or freeze-drying, removes water from the frozen material under controlled conditions.
For peptides, the resulting dry powder can be more practical to transport and store than a continuously aqueous formulation.
But lyophilized does not mean indestructible.
Environmental conditions still matter, especially:
-
humidity,
-
temperature,
-
container integrity,
-
and exposure time after opening.
That is why storage belongs in the research documentation chain.
Reconstitution: what a serious research guide should say
Tirzepatide research material is supplied in lyophilized form, so laboratory use requires preparation according to the specific material documentation and established laboratory procedures.
The American Peptides product page notes that reconstitution is suitable for laboratory assay preparation and directs researchers to its documentation for solvent recommendations.
A useful guide should stop there rather than turning a research article into a step-by-step human-use or injection protocol.
The important research principle is:
Use the validated preparation conditions required by the experiment and the supplier’s batch-specific documentation.
Tirzepatide and receptor research
Tirzepatide provides a particularly useful model for studying dual-receptor agonism.
Possible research questions include:
-
How does GIPR activation contribute to the overall signaling profile?
-
How does GLP-1R activity contribute?
-
How do the receptors respond to a single dual-active ligand?
-
Does receptor context alter downstream signaling?
-
How does lipidation influence receptor exposure?
-
How does tirzepatide compare with selective GLP-1 agonists?
These questions make the molecule valuable well beyond its clinical applications.
Tirzepatide and receptor-selective comparisons
A strong research comparison does not start with body weight.
It starts with receptor architecture.
For example:
Semaglutide
GLP-1R
Tirzepatide
GIPR + GLP-1R
Retatrutide
GIPR + GLP-1R + GCGR
This gives researchers a useful way to examine how additional receptor activity changes the experimental system.
The wider retatrutide guide in this cluster is here:
https://peptidesresearchguide.blogspot.com/2026/08/retatrutide-research-guide-2026.html
Tirzepatide and cagrilintide research
The two compounds represent different pathways.
Tirzepatide: GIP + GLP-1
Cagrilintide: amylin/calcitonin receptor systems
This makes them interesting from a mechanistic-comparison perspective.
The cagrilintide guide is available here:
https://juanparada1.substack.com/p/cagrilintide-research-guide-2026?r=8tof2y
Tirzepatide and retatrutide research
The relationship between tirzepatide and retatrutide is especially straightforward:
Retatrutide = tirzepatide-like dual incretin architecture + glucagon receptor activity
That is a conceptual simplification, not a structural statement.
The molecules are chemically different.
But from a receptor-map standpoint, the progression is useful:
GIP + GLP-1
versus
GIP + GLP-1 + glucagon
That explains why retatrutide is often discussed as a next-generation multi-receptor agonist.
Tirzepatide’s clinical evidence versus research-product evidence
This distinction deserves another explicit section because search results often blur it.
Clinical trials establish evidence about:
a defined pharmaceutical product + defined population + defined protocol + defined monitoring
A research-product COA establishes:
analytical information about a particular batch
Those are different evidence categories.
A clinical trial can tell you about efficacy and safety under its protocol.
A COA can tell you about measured analytical characteristics.
Neither should be used as a substitute for the other.
Why current regulatory status matters for a 2026 article
Older tirzepatide articles often stop at the 2022 Mounjaro approval and the 2023 Zepbound weight-management approval.
That is now incomplete.
The FDA approved Zepbound for obstructive sleep apnea in adults with obesity in December 2024, and the current FDA review record in 2026 reflects that expanded indication.
That makes 2026 a useful time to update tirzepatide content.
The molecule is no longer simply:
“a new diabetes drug.”
It has become a mature therapeutic platform with an expanding body of evidence across metabolic and sleep-related disease.
Common mistakes when researching tirzepatideMistake 1: Calling tirzepatide a GLP-1-only peptide
Tirzepatide is a dual GIP/GLP-1 agonist.
Mistake 2: Assuming GIP and GLP-1 are interchangeable
They are related incretin pathways, but they have distinct receptors and biological contexts.
Mistake 3: Treating dual agonism as automatic proof of superiority
Receptor count alone does not establish an outcome.
Mistake 4: Looking only at purity
Purity is one analytical attribute among many.
Mistake 5: Confusing research tirzepatide with Mounjaro or Zepbound
The molecular name may be the same, but the material category, formulation, manufacturing, and regulatory context can differ.
Mistake 6: Using clinical trial results as laboratory instructions
Clinical evidence is not a substitute for experimental methodology.
Mistake 7: Ignoring batch-level documentation
A generic certificate is less useful than one tied to the actual lot.
Mistake 8: Comparing prices without comparing quantity
A $100 single-vial price and a $84 bulk-unit price answer different purchasing questions.
How to evaluate a tirzepatide research supplier
A useful supplier evaluation can be reduced to a sequence.
1. Confirm identity
Does the supplier clearly identify tirzepatide?
2. Confirm the CAS number
Is it consistent with 2023788-19-2?
3. Check the COA
Is a lot-matched certificate available?
4. Examine HPLC testing
What does the chromatographic purity result actually show?
5. Examine mass spectrometry
Does the measured mass support the expected peptide?
6. Check independent testing
Is third-party testing described and documented?
7. Review the SDS
Is safety documentation available?
8. Check storage requirements
Are the handling conditions explicit?
9. Review the research-use designation
Is the product clearly identified as research material?
10. Compare batch documentation
Are similar analytical standards applied across different lots?
11. Evaluate the price structure
What is the actual per-unit cost at the quantity required?
12. Check availability
Is the exact configuration currently in stock?
This framework makes supplier comparison much more objective.
American Peptides’ COA system
American Peptides currently maintains a public COA library that describes its certificates as lot-matched and says batches are independently third-party tested for identity and purity at ≥99% by HPLC/MS.
The current library lists multiple tirzepatide certificates, including:
-
10 mg
-
20 mg
-
60 mg
-
100 mg
This is useful because it lets a researcher compare the documentation at the batch level rather than relying solely on the product-page description.
What the current tirzepatide research page says
American Peptides’ educational tirzepatide reference describes the molecule as:
-
a 39-amino-acid synthetic peptide,
-
a GIP/GLP-1 dual agonist,
-
C20 lipid-conjugated,
-
lyophilized,
-
and suitable for laboratory research.
It also describes analytical characterization using HPLC for purity and mass spectrometry for molecular identity.
Again, the most useful verification step is to inspect the actual batch certificate.
Current tirzepatide pricing
At the time of this article’s research, American Peptides displayed:
10 mg — $100
with volume pricing:
3–4 units — $93 each
5–9 units — $89 each
10+ units — $84 each
The 30 mg and 100 mg configurations were shown as currently sold out on the crawled product page, illustrating why price articles should avoid pretending availability is permanent.
Pricing can change, so the product page should remain the final source for current availability.
Where the LOOT10 promotion fits
For readers who have already compared the molecular profile, testing documentation, and current pricing, the supplied LOOT10 promotion is the commercial detail worth checking.
The current offer provided for this guide is:
**Promo code: **<code inline=””>LOOT10
Advertised saving: up to 30% off
Offer page:
https://www.americanpeptides.us/loot30
Because American Peptides already displays quantity-based pricing and subscription savings, the sensible comparison is the actual final price for the exact configuration and quantity, not simply the headline percentage.
That is the difference between using a coupon as a useful price tool and building an article around a coupon.
How to compare the coupon with volume pricing
Suppose the displayed starting price is $100 for 10 mg.
The site also displays:
-
$93 at 3–4 units
-
$89 at 5–9 units
-
$84 at 10+ units
A separate percentage promotion may interact with current promotional conditions differently.
So the meaningful question is not:
“Which percentage is bigger?”
It is:
“What final price appears for the exact cart I am evaluating?”
That is the number worth recording.
Why price per unit can be misleading
Researchers should distinguish between:
price per vial
and
price per amount of material
and, where relevant,
price per analytically characterized batch
Those are not necessarily the same comparison.
A lower sticker price can become less attractive if:
-
the configuration is smaller,
-
documentation is weaker,
-
availability is inconsistent,
-
or the quantity structure does not match the research requirement.
This is why quality and price should be evaluated together.
A practical tirzepatide COA checklist
When reviewing a certificate, use the following order.
Step 1 — Identify the molecule
Confirm tirzepatide and the chemical identifiers.
Step 2 — Match the lot
Ensure the certificate corresponds to the batch.
Step 3 — Verify the analytical methods
Look for HPLC and mass spectrometry.
Step 4 — Read the actual results
Don’t rely only on a headline purity number.
Step 5 — Check the molecular mass
Does it support the expected structure?
Step 6 — Review the test date
Establish when the batch was tested.
Step 7 — Check additional documents
Look for an SDS and any relevant supplementary reports.
Step 8 — Compare with laboratory requirements
Not every research project needs the same analytical profile.
A useful evidence hierarchy for tirzepatide
When reading online material, it helps to rank information by what it actually establishes.
Level 1: Chemical-reference information
Examples:
-
molecular formula,
-
CAS,
-
molecular weight,
-
peptide length.
Sources such as PubChem are useful here.
Level 2: Analytical batch documentation
Examples:
-
HPLC purity,
-
mass spectrometry,
-
lot number,
-
testing date.
Supplier COAs are relevant here.
Level 3: Preclinical research
Examples:
-
receptor signaling,
-
animal models,
-
cell-based experiments.
These can explain mechanisms but do not automatically predict clinical outcomes.
Level 4: Clinical trials
Examples:
-
SURPASS
-
SURMOUNT
These provide human evidence under defined protocols.
Level 5: Regulatory decisions
FDA approvals address specific products and indications.
For tirzepatide, that includes Mounjaro and Zepbound.
Keeping those levels separate is one of the simplest ways to avoid misleading peptide content.
Why this evidence hierarchy improves research writing
A lot of online peptide material mixes:
a chemical formula
with
a clinical trial
with
a supplier’s purity claim
and then draws one sweeping conclusion.
That is poor scientific communication.
A better approach is:
Chemical identity → analytical characterization → mechanistic evidence → clinical evidence → regulatory status
Each layer answers a different question.
Tirzepatide research guide FAQWhat is tirzepatide research peptide?
Tirzepatide is a synthetic 39-amino-acid peptide engineered as a dual GIP/GLP-1 receptor agonist. Research-use tirzepatide is supplied as laboratory material and should not be treated as automatically equivalent to an approved pharmaceutical product.
What is tirzepatide’s CAS number?
The CAS number is 2023788-19-2.
What receptors does tirzepatide target?
Tirzepatide activates the GIP receptor and GLP-1 receptor.
Why is tirzepatide called a dual agonist?
Because one engineered peptide activates two receptor systems: GIPR and GLP-1R.
How many amino acids are in tirzepatide?
Tirzepatide is a 39-amino-acid peptide.
What is tirzepatide’s molecular formula?
The molecular formula is C225H348N48O68.
What is the molecular weight of tirzepatide?
PubChem lists approximately 4,813 g/mol, while American Peptides lists 4,813.45 g/mol for its research material.
Why does tirzepatide contain a C20 fatty-diacid?
The lipidated side chain is part of the molecule’s long-acting design and supports reversible association with albumin, which contributes to its prolonged pharmacokinetic profile.
What is the role of Aib in tirzepatide?
Aib is a non-proteinogenic amino acid incorporated into the engineered peptide structure. It can influence peptide conformation and resistance to enzymatic degradation.
How is tirzepatide different from semaglutide?
Semaglutide is primarily a GLP-1 receptor agonist, while tirzepatide activates both GIP and GLP-1 receptors. Direct clinical trials have compared the two in both diabetes and obesity populations.
How is tirzepatide different from retatrutide?
Tirzepatide targets GIP and GLP-1 receptors. Retatrutide adds glucagon receptor activity, creating a GIP/GLP-1/glucagon triple-agonist architecture.
How is tirzepatide different from cagrilintide?
Tirzepatide is a GIP/GLP-1 dual agonist. Cagrilintide is an amylin analogue acting through amylin/calcitonin receptor systems.
Is tirzepatide FDA approved?
Yes. Tirzepatide is the active ingredient in FDA-approved Mounjaro and Zepbound products. Mounjaro was approved for glycemic control in adults with type 2 diabetes, while Zepbound was approved for chronic weight management and later for moderate-to-severe obstructive sleep apnea in adults with obesity.
What is Mounjaro?
Mounjaro is the Eli Lilly brand name for tirzepatide approved in the United States for improving blood glucose control in adults with type 2 diabetes alongside diet and exercise.
What is Zepbound?
Zepbound is the Eli Lilly brand name for tirzepatide approved for defined chronic weight-management indications and, as of December 2024, moderate-to-severe obstructive sleep apnea in adults with obesity.
Is research-grade tirzepatide the same as Mounjaro or Zepbound?
It should not be assumed to be equivalent. Research material and FDA-approved pharmaceutical products can differ in formulation, manufacturing controls, quality systems, packaging, regulatory status, and intended use.
What does ≥99% tirzepatide purity mean?
It is an analytical purity specification. It does not by itself establish sterility, clinical efficacy, pharmaceutical equivalence, or regulatory approval.
Why is a lot-matched tirzepatide COA important?
It connects the analytical results to a particular batch, providing stronger traceability than a generic certificate.
What does HPLC testing tell you about tirzepatide?
HPLC provides chromatographic information that can be used to evaluate purity and distinguish the target peptide from detectable related substances.
What does mass spectrometry tell you about tirzepatide?
Mass spectrometry provides molecular-mass information that can support characterization of the peptide’s molecular identity.
What is the current American Peptides tirzepatide price?
The current displayed starting price is $100 for 10 mg, with volume pricing shown at $93, $89, and $84 per unit for larger quantities. Availability varies by configuration.
Does American Peptides offer multiple tirzepatide research configurations?
Yes. The current product page lists 10 mg, 20 mg, 30 mg, 60 mg, and 100 mg, although some configurations may be sold out at a particular moment.
Does American Peptides provide tirzepatide COAs?
Yes. The current COA library lists lot-matched tirzepatide certificates for several configurations.
Does American Peptides third-party test tirzepatide?
American Peptides states that its batches are independently third-party tested for identity and purity and that the tirzepatide product has ≥99% HPLC/mass-spectrometry verification. The underlying lot-specific COA is the most useful document to review.
How should lyophilized tirzepatide research material be stored?
American Peptides currently lists storage of its dry tirzepatide material at approximately −20°C, protected from light and moisture. Follow the product documentation associated with the actual batch.
Does American Peptides offer a tirzepatide promo code?
The promotion supplied for this guide is LOOT10, advertised for up to 30% off through the associated offer.
How can I check the current LOOT10 tirzepatide discount?
The supplied current offer is:
https://www.americanpeptides.us/loot30
The final applicable discount should be verified against the current promotion and cart.
Does LOOT10 guarantee 30% off every tirzepatide configuration?
No. The supplied promotion is described as up to 30% off, so the actual saving should be checked against the current terms and the specific order.
Further reading and related guides
This article is part of a broader research-peptide knowledge cluster.
Retatrutide Research Guide 2026
A detailed examination of LY3437943, GIP/GLP-1/glucagon triple-agonist biology, molecular structure, testing, COAs, and current research status:
https://peptidesresearchguide.blogspot.com/2026/08/retatrutide-research-guide-2026.html
Cagrilintide Research Guide 2026
A dedicated guide to amylin biology, receptor architecture, molecular structure, clinical-development evidence, COAs, and laboratory research:
https://juanparada1.substack.com/p/cagrilintide-research-guide-2026?r=8tof2y
Retatrutide + Cagrilintide Research Guide
A comparison of the distinct signaling architectures behind the triple-agonist retatrutide and the amylin analogue cagrilintide:
Semaglutide Research Guide
A related GLP-1-focused guide covering molecular structure, lipidation, receptor biology, COA interpretation, and laboratory research:
Supporting research/promotional reference
https://gist.github.com/waseemsahirofficial2-dev/2dc0806c9536dfd8893a0c60ccc91a41
The GitHub Gist is best treated as a supporting reference for the promotional side of the content cluster rather than as an authority for scientific or regulatory claims.
The bottom line on tirzepatide
Tirzepatide is one of the clearest examples of how peptide drug design has moved from single-receptor agonism toward multi-receptor pharmacology.
Its defining mechanism is:
GIP receptor + GLP-1 receptor
Its defining structural features include:
39 amino acids + engineered residues + C20 lipid conjugation + linker architecture
Its research value spans several layers:
-
receptor pharmacology,
-
incretin biology,
-
peptide chemistry,
-
pharmacokinetics,
-
analytical characterization,
-
and clinical development.
The clinical evidence is also extensive.
SURPASS studies established major effects in type 2 diabetes, while SURMOUNT trials expanded the evidence into obesity and long-term metabolic outcomes. Direct comparisons with semaglutide provide unusually useful evidence about the differences between GLP-1-only and dual GIP/GLP-1 pharmacology.
The regulatory picture has continued to develop as well. Tirzepatide is now represented by FDA-approved Mounjaro and Zepbound products, with Zepbound’s U.S. labeling extending to moderate-to-severe obstructive sleep apnea in adults with obesity.
For researchers evaluating a tirzepatide research material, however, the clinical story should never replace the analytical story.
The useful checklist is:
Confirm the molecular identity.
Understand the GIP/GLP-1 receptor architecture.
Review the peptide structure.
Check the lot-matched COA.
Understand what HPLC measures.
Understand what mass spectrometry measures.
Distinguish analytical purity from broader quality.
Separate research material from pharmaceutical product.
Then compare current pricing.
That last step is where the supplied LOOT10 promotion can become relevant.
The current offer provided for this guide is:
Promo code: <code inline=””>LOOT10 — up to 30% off
Offer:
https://www.americanpeptides.us/loot30Because the American Peptides product page currently also shows volume-based pricing, compare the final applicable price for the exact configuration and quantity rather than assuming the advertised maximum discount applies to every order.
peptidesresearchguide.blogspot.com
Retatrutide Research Guide 2026: Molecular Profile, Triple-Agonist Biology, Testing & LOOT10 Savings
Retatrutide, also known as LY3437943 , is an investigational 39-amino-acid peptide designed to activate three metabolic hormone receptors: G...
-
-
0 Replies
Sorry, there were no replies found.
Log in to reply.